Differentiated use of proton pump inhibitors in patients receiving antiplatelet therapy (review of literature)



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

In cardiovascular diseases, all patients are shown lifelong antithrombotic therapy to prevent cardiovascular complications. The use of antiplatelet agents, along with a reduced risk of thrombotic complications, entails negative consequences in the form of an increased likelihood of bleeding. The article presents a review of literature data on modern approaches to the use of antiplatelet drugs for cardiovascular diseases and proton pump inhibitors as gastroprotection of gastroduodenal erosive and ulcerative complications. Given the inter - drug interaction of these drugs, an algorithm is proposed for the differential use of proton pump inhibitors in patients receiving antiplatelet therapy. It is concluded that such use of these agents in comorbid cardiovascular and gastroduodenal pathology can reduce risks from both the cardiovascular system and the gastrointestinal tract.

Full Text

Restricted Access

References

  1. Диагностика и лечение больных острым инфарктом миокарда с подъемами сегмента ST электрокардиограммы: Рекомендации Общества специалистов по неотложной кардиологии и профильной комиссией по кардиологии. - М.: МЗ РФ. - 2014.
  2. Зверева С.И., Еремина Е.Ю., Рябова Е.А. Распространенность и особенности гастроэфагеальной рефлюксной болезни и ишемической болезни сердца // Мед. альманах. - 2011. - № 2 (15). - С. 103-106.
  3. Крашутский В.В., Пырьев А.Н. Гемостаз при гастродуоденальных кровотечениях // Госпит. медицина: наука и практика. - 2019. - Т. 1, № 4. - С. 21-31.
  4. Маев И.В., Андреев Д.Н., Кочетов С.А., Дичева Д.Т. Фармакологические и гастроэнтерологии. - М., 2012. - С. 38-45.
  5. Симонова Ж.Г., Мартусевич А.К., Тарловская Е.И. Сочетанная патология сердечно - сосудистой системы и желудочно - кишечного тракта. - Киров, 2013. - 132 с.
  6. Хворостинка В.Н., Колесникова Е.В., Цивенко О.И. Особенности течения язвенной болезни, ассоциированной с ишемической болезнью сердца // Украiнский тер. журн. - 2005. - № 4. - С. 52-56.
  7. Aboyans V., Ricco J.B., Bartelink M. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) // Eur. Heart J. - 2017. - Aug. 26.
  8. Antithrombotic Trialists’ Collaboration. Collaborative meta - analysis of randomized trials of antiplatelet therapy for prevention of death, MI, and stroke in high risk patients // BMJ. -2002. - Vol. 324 , N 7329. - Р. 71-86.
  9. Baumgartner H., Falk V., Bax J.J. et al. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease // Eur. Heart J. - 2017. - Vol. 38, N 36. - Р. 2739-2791.
  10. Belabic J.M. Ticagrelor: A new option for ACS // Nurce Pract. - 2012. - Vol. 37, N 3. - Р. 9-11.
  11. Gilard M., Arnaud B., Cornily J.C. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double - blind OCLA (Omeprazole Clopidogrel Aspirin) study // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - Р. 256-260.
  12. Gutermann I.K., Niggemeier V., Zimmerli L.U. et al. Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines // Medicine (Baltimore). - 2015. - Vol. 94, N 1. - Р. 377.
  13. Ibanez B., James S., Agewall S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation // Eur. Heart J. - 2018. - Vol. 39, N 2. - Р. 119-177.
  14. Kazui M., Nishiya Y., Ishizuka T. et al. Identification of the human cytochrome 450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metadolite // Drag, Metab. Dispos. - 2010. - Vol. 38, N 1. - Р. 92-99.
  15. Laine L., Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? // Am. J. Gastroenterol. - 2010. - Vol. 105. - Р. 34-41.
  16. Li X.Q., Andersson T.B., Ahlstrom M. et al. Comparison of inhibitory effects of the proton pump - inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities // Drug Metab. Disp. - 2004. - Vol. 32. - Р. 821-827.
  17. Montalescot G., Sechtem U. et al. 2013 ESC guidelines on the management of stable coronary artery disease // Eur Heart J. - 2013. - Vol. 34, N 38. - Р. 2949-3003.
  18. Paikin J.S., Eicelboom J.W., Cairns J.A., Hirsh J. New antitrombotic agents-insights from clinical trials // Nature Rev. Cardiol. - 2010. - Vol. 7, N 9. - Р. 498-509.
  19. Roffi M., Patrono C., Collet J.P. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation // Eur. Heart J. - 2016. - Vol. 37, N 3. - P. 267-315.
  20. Shin J.M., Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors // J. Neurogastroenterol Motil. - 2013. - Vol. 19, N 1. - Р. 25-35.
  21. Shuldiner A.R., O’Connell J.R., Bliden K.P. et al. Association of cytochrome P4502C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy // JAMA. - 2009. - Vol. 302. - Р. 849-857.
  22. Simon T., Verstuyft C., Mary-Krause M. et al. Genetic determinants of response to clopidogrel and cardiovascular events // N. Engl. J. Med. - 2009. - Vol. 360, N 4. - Р. 363-375.
  23. Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS // Eur. Heart J. - 2018. - Vol. 39, N 3. - Р. 213-260.

Copyright (c) 2020 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies